[go: up one dir, main page]

MX2018012383A - Método para alterar la retención en plasma e inmunogenicidad de la molécula de union al antígeno. - Google Patents

Método para alterar la retención en plasma e inmunogenicidad de la molécula de union al antígeno.

Info

Publication number
MX2018012383A
MX2018012383A MX2018012383A MX2018012383A MX2018012383A MX 2018012383 A MX2018012383 A MX 2018012383A MX 2018012383 A MX2018012383 A MX 2018012383A MX 2018012383 A MX2018012383 A MX 2018012383A MX 2018012383 A MX2018012383 A MX 2018012383A
Authority
MX
Mexico
Prior art keywords
antigen
amino acid
acid position
binding activity
binding
Prior art date
Application number
MX2018012383A
Other languages
English (en)
Inventor
Tomoyuki Igawa
Futa Mimoto
Taichi Kuramochi
Shojiro Kadono
Atsuhiko Maeda
Kenta Haraya
Yuki Iwayanagi
Tatsuhiko Tachibana
Hitoshi Katada
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2011/001888 external-priority patent/WO2011122011A2/en
Priority claimed from PCT/JP2011/072550 external-priority patent/WO2012132067A1/ja
Priority claimed from PCT/JP2012/054624 external-priority patent/WO2012115241A1/ja
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority claimed from PCT/JP2012/058603 external-priority patent/WO2012133782A1/ja
Publication of MX2018012383A publication Critical patent/MX2018012383A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una molécula de unión al antígeno seleccionada de IgG1, IgG2, IgG3 e IgG4 que comprende un dominio de unión al antígeno cuya actividad de unión al antígeno varía dependiendo de pH, en donde la actividad de unión al antígeno en pH 5.8 es más débil que la actividad de unión al antígeno en pH 7.4, y una región Fc que tiene (i) actividad de unión a FcRn en pH 7.4 y (ii) activar actividad de unió a FC¿R que es inferior a la actividad de unión de IgG1 humana nativa para el FC¿R de activación, en donde la activación de actividad de unión a Fc¿R se determina a pH 7.4, caracterizada porque la región Fc comprende uno o más aminoácidos seleccionados de: Lys, o Arg en posición 235 del aminoácido: Arg en posición 238 del aminoácido: Lys en posición 239 del aminoácido; Phe en posición 270 del aminoácido: Gly en posición 298 del aminoácido; Gly en posición 325 del aminoácido; Lys o Arg en posición 329 del aminoácido; en donde los aminoácidos se indican por numero de UE.
MX2018012383A 2011-03-30 2012-03-30 Método para alterar la retención en plasma e inmunogenicidad de la molécula de union al antígeno. MX2018012383A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/JP2011/001888 WO2011122011A2 (en) 2010-03-30 2011-03-30 Antibodies with modified affinity to fcrn that promote antigen clearance
PCT/JP2011/072550 WO2012132067A1 (ja) 2011-03-30 2011-09-30 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
PCT/JP2012/054624 WO2012115241A1 (ja) 2011-02-25 2012-02-24 FcγRIIb特異的Fc抗体
PCT/JP2012/058603 WO2012133782A1 (ja) 2011-03-30 2012-03-30 抗原結合分子の血漿中滞留性と免疫原性を改変する方法

Publications (1)

Publication Number Publication Date
MX2018012383A true MX2018012383A (es) 2023-03-07

Family

ID=79745360

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012383A MX2018012383A (es) 2011-03-30 2012-03-30 Método para alterar la retención en plasma e inmunogenicidad de la molécula de union al antígeno.

Country Status (6)

Country Link
US (1) US20230257470A1 (es)
JP (2) JP7779878B2 (es)
KR (3) KR102639563B1 (es)
CN (2) CN113980952A (es)
CA (1) CA3236171A1 (es)
MX (1) MX2018012383A (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
JP6226752B2 (ja) 2012-02-09 2017-11-08 中外製薬株式会社 抗体のＦｃ領域改変体
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100887482B1 (ko) 1999-01-15 2009-03-10 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP3321282A1 (en) 2002-09-27 2018-05-16 Xencor, Inc. Optimized fc variants and methods for their generation
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
SI2471813T1 (sl) 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
CA2700986A1 (en) 2007-09-28 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma
DK2808343T3 (da) * 2007-12-26 2019-08-19 Xencor Inc Fc-varianter med ændret binding til FcRn
EP2708559B1 (en) * 2008-04-11 2018-03-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI440470B (zh) * 2009-03-19 2014-06-11 Chugai Pharmaceutical Co Ltd 含改良抗體分子之醫藥配方
MY164121A (en) * 2009-06-26 2017-11-30 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format

Also Published As

Publication number Publication date
JP7779878B2 (ja) 2025-12-03
KR102639563B1 (ko) 2024-02-21
JP2023106564A (ja) 2023-08-01
KR102403848B1 (ko) 2022-05-30
CN113999307A (zh) 2022-02-01
KR102899019B1 (ko) 2025-12-10
CN113980952A (zh) 2022-01-28
KR20200121900A (ko) 2020-10-26
KR20220075441A (ko) 2022-06-08
JP2025176095A (ja) 2025-12-03
CA3236171A1 (en) 2012-10-04
US20230257470A1 (en) 2023-08-17
KR20240027154A (ko) 2024-02-29

Similar Documents

Publication Publication Date Title
ES2689080T3 (es) Anticuerpos que se unen a TL1A y sus usos
CY1125302T1 (el) Συναγωνιστες γλυκαγονης και glp-1 για την αγωγη της παχυσαρκιας
PE20221909A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
MX386942B (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
PE20091388A1 (es) Moleculas y metodos para modular el componente de complemento
CR20140029A (es) Proteínas de unión a antígeno de tnf-alfa con unión a fcrn incrementada
ECSP14001260A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas
BR112013029525A8 (pt) Proteínas de fusão terapêuticas
UA117294C2 (uk) Імунокон'югат
BR112016014913A8 (pt) anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
BR112013027829A2 (pt) anticorpos anti-cd40 e método de uso
PE20170142A1 (es) Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma
CO6331370A2 (es) Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
EA201490815A1 (ru) Составы этанерцепта, стабилизированные с помощью аминокислот
NI201300130A (es) Composiciones que contienen, metodos que involucran, y usos de derivados de dolastatina unidos a aminoácidos no naturales
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
AR085955A1 (es) Proteinas de union al antigeno
BRPI0912570B8 (pt) anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos
UA115906C2 (uk) Fc-ФРАГМЕНТ ІМУНОГЛОБУЛІНУ IgG4, ЯКИЙ МАЄ МОДИФІКОВАНУ ШАРНІРНУ ДІЛЯНКУ
BR112014017814A8 (pt) Anticorpos anti-cxcr3
MX371328B (es) Constructo de fusion de la fraccion efectora del fragmento de union a antigeno (fab) de anti-albumina de suero y su metodo de preparacion.
CO7270463A2 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición